Insider Selling: Ionis Pharmaceuticals Inc (IONS) SVP Sells 12,500 Shares of Stock

Ionis Pharmaceuticals Inc (NASDAQ:IONS) SVP C Frank Bennett sold 12,500 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $52.50, for a total value of $656,250.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

C Frank Bennett also recently made the following trade(s):

  • On Tuesday, January 16th, C Frank Bennett sold 2,696 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $51.76, for a total value of $139,544.96.

Ionis Pharmaceuticals Inc (IONS) opened at $51.11 on Friday. Ionis Pharmaceuticals Inc has a 52 week low of $37.26 and a 52 week high of $65.51. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. The stock has a market capitalization of $6,170.00, a PE ratio of 365.07 and a beta of 2.53.

Institutional investors and hedge funds have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC purchased a new position in Ionis Pharmaceuticals in the third quarter valued at about $100,000. Parallel Advisors LLC grew its stake in Ionis Pharmaceuticals by 60.3% in the third quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock valued at $182,000 after purchasing an additional 1,250 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares during the last quarter. WFG Advisors LP grew its stake in Ionis Pharmaceuticals by 77.2% in the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after purchasing an additional 1,655 shares during the last quarter. Finally, CIBC Asset Management Inc purchased a new position in Ionis Pharmaceuticals in the third quarter valued at about $212,000. Institutional investors own 91.43% of the company’s stock.

IONS has been the topic of several research reports. Stifel Nicolaus restated a “hold” rating and set a $50.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. BidaskClub upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price target on the stock in a research note on Friday, October 27th. Morgan Stanley raised their price target on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Finally, BMO Capital Markets raised their price target on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $50.76.

COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2018/02/03/insider-selling-ionis-pharmaceuticals-inc-ions-svp-sells-12500-shares-of-stock.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit